Abstract

CURATIVE THERAPY FOR HEPATOCELLULAR CARCINOMA: A REVIEW

Smriti Singh Rajpoot, Shubham Patel, Shubham Prajapati, Akash Jain, Mahak Jain*

Adina Institute of Pharmaceutical Sciences, Sagar (M.P.)

ABSTRACT

Hepatocellular carcinoma (HCC) is a type of liver cancer that is becoming more frequent. A variety of potentially curative treatments have become accessible as a result of advancements in surgical techniques and technology, as well as the development of molecular-target medications. The treatment of HCC patients is determined on the stage of their cancer. Although liver resection remains the treatment of choice for very early-stage HCC, local ablative therapy is posing a threat. HCC is the most common type of primary liver cancer and the second-leading cause of death worldwide. HCC is more common in persons with liver cirrhosis in the Western world. As a result, the use of locoregional therapies and systemic agents should be based on a multidisciplinary assessment, which should include, above all, consideration of the functional liver reserve. The current treatment lines and novel tactics in the management of HCC are summarised in this study.

Keywords: Hepatocellular carcinoma, Curative intent treatment, Targeted Agents.